Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 50:1967-1972, doi:10.1016/j.jacc.2007.07.068 (Published online 29 October 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.07.068v1
50/20/1967    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arora, S.
Right arrow Articles by Gullestad, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arora, S.
Right arrow Articles by Gullestad, L.

CLINICAL RESEARCH: HEART FAILURE

Pre-Transplant Toxoplasma gondii Seropositivity Among Heart Transplant Recipients Is Associated With an Increased Risk of All-Cause and Cardiac Mortality

Satish Arora, MD*,*, Pål A. Jenum, MD, PhD{dagger},||, Pål Aukrust, MD, PhD{ddagger}, Halvor Rollag, MD, PhD{dagger}, Arne K. Andreassen, MD, PhD*, Svein Simonsen, MD, PhD*, Einar Gude, MD*, Arnt E. Fiane, MD, PhD§, Odd Geiran, MD, PhD§ and Lars Gullestad, MD, PhD*

* Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
{dagger} Institute of Medical Microbiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
{ddagger} Section of Clinical Immunology and Infectious Diseases, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
§ Department of Thoracic and Cardiovascular Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
|| Department of Microbiology, Central Laboratory, Hospital of Asker and Baerum, Oslo, Norway
Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway.

Manuscript received April 10, 2007; revised manuscript received June 22, 2007, accepted July 30, 2007.

* Reprint requests and correspondence: Dr. Satish Arora, Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, N-0027 Oslo, Norway. (Email: satish.arora{at}medisin.uio.no).

Objectives: We evaluated the risk of mortality, development of cardiac allograft vasculopathy (CAV), and acute cellular rejection among Toxoplasma gondii (T. gondii) seropositive heart transplant (HTx) recipients and the 4 donor/recipient seropairing groups.

Background: Chronic T. gondii infection is known to trigger potentially adverse immunoregulatory changes, but the long-term implication for HTx recipients has not been assessed previously.

Methods: Frozen pre-HTx serum samples of 288 recipients and 246 donors were evaluated for T. gondii serostatus using Platelia immunoglobulin G immunoassay. Patients had undergone prospective serotesting using alternative assays, and results determined by the 2 methods were compared. Data regarding mortality, CAV, and acute cellular rejection were available for all patients.

Results: Overall, 211 recipients (73%) were seronegative and 77 (27%) were seropositive. In total, 82 recipients died, 76 developed CAV, and 82 had 1 or more episode of treated cellular rejection. Recipient seropositivity was associated with a significantly higher risk of all-cause (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1 to 3.4; p = 0.02) and CAV mortality (HR 4.4, 95% CI 1.3 to 15.6; p = 0.02) and a higher risk of developing advanced CAV (HR 2.7, 95% CI 1.2 to 5.8; p = 0.01). Seropositivity did not influence the number of rejection episodes, and donor/recipient seropairing was not a risk factor for any end point.

Conclusions: T. gondii seropositivity among HTx recipients is associated with an increased risk of all-cause and CAV mortality and of development of advanced CAV. This may be mediated via immunoregulatory changes triggered by chronic T. gondii infection and needs to be explored further.

Abbreviations and Acronyms
  CAV = cardiac allograft vasculopathy
  CMV = cytomegalovirus
  EIA = enzyme immunoassay
  HTx = heart transplant/transplantation
  IFN = interferon
  IL = interleukin
  R = recipient
  T. gondii = Toxoplasma gondii




This article has been cited by other articles:


Home page
Clin Kidney JHome page
B. Hebraud, N. Kamar, J.-S. Borde, M.-H. Bessieres, M. Galinier, and L. Rostaing
Unusual presentation of primary toxoplasmosis infection in a kidney-transplant patient complicated by an acute left-ventricular failure
Clinical Kidney Journal, December 1, 2008; 1(6): 429 - 432.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
X. Flores-Rios, M. J. Paniagua-Martin, J. Muniz-Garcia, and M. G. Crespo-Leiro
Pre-Transplant Toxoplasma gondii Seropositivity Among Heart Transplant Recipients and Mortality
J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1827 - 1827.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Arora, P. A. Jenum, P. Aukrust, H. Rollag, A. K. Andreassen, S. Simonsen, E. Gude, A. E. Fiane, O. Geiran, and L. Gullestad
Reply
J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1827 - 1828.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement